SALT LAKE CITY, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced two significant ...
Discover why Recursion Pharmaceuticals, Inc. stands out in AI drug discovery, but faces valuation risks. Click for my look at ...
At ELRIG’s 2025 meeting in GSK’s Stevenage campus, Recursion’s Executive Director of Computational Biology, Dr. Kelly ...
Whenever machine learning is applied to a given field of industry, defining the objective is one of the most salient questions. Just what are you trying to find out? In the biological sciences, that ...
After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week.
Salt Lake City, UT, April 22, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, will present preliminary data ...
With additional patient-centric data, compute power, and an exciting new focus for its Bayer collaboration, the company is accelerating the shift of biotech to techbio SALT LAKE CITY, Nov. 09, 2023 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback